Looking Ahead: Future Perspectives on AL Amyloidosis

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

EP: 4.Current Treatment Landscape for AL Amyloidosis

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

Now Viewing

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Looking ahead, future directions in light chain (AL) amyloidosis involve crucial advancements. With the need for improved outcomes, priorities include enhancing early diagnosis through artificial intelligence and machine learning, reducing the educational gap, and increasing awareness. Antifibril agents, particularly chimeric antigen receptor T cells and bispecifics, are emerging as promising therapies, leveraging the success seen in myeloma treatments. Notably, the use of venetoclax and Bcl-2 inhibitors holds promise, especially for patients with the translocation(11;14), constituting around 50% of AL amyloidosis cases. A critical goal is the expansion of the therapeutic landscape, with focus on deep hematologic responses achievable with small doses of innovative agents.

Additionally, advancements in diagnostic tools are anticipated, such as better imaging modalities for assessing organ involvement. The amyloid community looks forward to the results of ongoing studies and the potential incorporation of antifibril strategies. Notably, a new amyloid assay aims to identify patients and predict toxicity or mortality risk. With these developments, there is optimism about chipping away at the challenges faced within the first 100 days of treatment, offering hope for improved outcomes in the amyloidosis patient population.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.